Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Lung cancer screening adherence rates decline annually after baseline screening

2.

MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA

3.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

4.

World's premier cancer institute faces crippling cuts and chaos

5.

Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot